Dibotermin alfa | CAS# 246539-15-1 | osteoinductive protein

MedKoo Cat#: 413676 | Name: Dibotermin alfa

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dibotermin alfa is a potent osteoinductive protein that plays a critical role in the differentiation of osteoprogenitor cells into OSTEOBLASTS.

Chemical Structure

Dibotermin alfa

CAS#246539-15-1

Theoretical Analysis

MedKoo Cat#: 413676

Name: Dibotermin alfa

CAS#: 246539-15-1

Chemical Formula: C658H1010N192O186S9

Exact Mass: 14865.2962

Molecular Weight: 14875.02

Elemental Analysis: C, 53.13; H, 6.84; N, 18.08; O, 20.01; S, 1.94

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Dibotermin alfa; BMP2; BMP-2; BMP 2

IUPAC/Chemical Name

None

InChi Key

InChi Code

SMILES Code

CC[C@@H]([C@@H]1NC(C(NC(C(NC(C(NC(C(C(C)C)NC(C(NC(C(NC(C(C(C)C)NC(C(NC([C@H]([C@H](O)C)NC(C(NC(C(C(C)C)NC([C@H]([C@H](CC)C)NC(C(NC(C(NC(C(NC([C@H]([C@H](O)C)NC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C(NC(C2CccN2C(C(NC(C3CCCN3C([C@@H]4CSSC[C@@H](C(N[C@H](C(O)=O)CCCNC(N)=N)=O)NC(CNC(C5CSSC[C@@H](C(N[C@H](C(NCC(N[C@H](C(N4)=O)CCC(O)=O)=O)=O)Cc6[nH]cnc6)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H]7CCCN7C([C@@H]8CCCN8C([C@@H](NC([C@H](c(c)c)NC([C@H]([C@H](CC)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@@H]9CCCN9C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H]%10CCCN%10C([C@@H](NC(CNC([C@@H](NC(CNC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@H]([C@H](O)C)N)=O)Cc%11ccccc%11)=O)=O)Cc%12[nH]cnc%12)=O)CC(O)=O)=O)=O)CCCCN)=O)=O)Cc%13[nH]cnc%13)=O)=O)CC(C)C)=O)Cc%14[nH]cnc%14)=O)CCCCN)=O)CCCNC(N)=N)=O)CCC(O)=O)=O)CCCCN)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)C)=O)CCCCN)=O)Cc%15[nH]cnc%15)=O)CCCCN)=O)CCC(N)=O)=O)CCCNC(N)=N)=O)CCCCN)=O)CCCNC(N)=N)=O)CC(C)C)=O)CCCCN)=O)CO)=O)CO)=O)CSSC[C@@H](C(N[C@H](C(N%16CCC[C@H]%16C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N5)=O)=O)CCC(O)=O)=O)C(C)C)=O)C(C)C)=O)CCSC)=O)CC(O)=O)=O)CCC(N)=O)=O)Cc%17ccc(O)cc%17)=O)CC(N)=O)=O)CCCCN)=O)CC(C)C)=O)C(C)C)=O)C(C)C)=O)CCCCN)=O)CCC(O)=O)=O)CC(N)=O)=O)CCC(O)=O)=O)CC(O)=O)=O)CC(C)C)=O)Cc%18ccc(O)cc%18)=O)CC(C)C)=O)CCSC)=O)CO)=O)[C@H](CC)C)=O)C)=O)CO)=O)CC(C)C)=O)CCC(O)=O)=O)[C@H](O)C)=O)=O)C(C)C)=O)NC(C(NC(C(NC(C(NC(C%19CCCN%19C1=O)=O)CCCCN)=O)C)=O)CS)=O)=O)CCCCN)=O)CCCNC(N)=N)=O)Cc%20[nH]cnc%20)=O)=O)CC(C)C)=O)Cc%21ccc(O)cc%21)=O)=O)CC(O)=O)=O)Cc%22ccccc%22)=O)CO)=O)CC(O)=O)=O)=O)=O)Cc(c[nH]%23)c%24c%23cccc%24)=O)cc(=O)[nH2])=O)CC(O)=O)=O)Cc(c[nH]%25)c%26c%25cccc%26)=O)=O)=O)C)=O)=O)=O)=O)Cc%27ccc(O)cc%27)=O)Cc%28[nH]cnc%28)=O)C)=O)Cc%29ccccc%29)=O)Cc%30ccc(O)cc%30)=O)=O)=O)=O)=O)Cc%31ccccc%31)=O)=O)CC(C)C)=O)C)=O)CC(O)=O)=O)Cc%32[nH]cnc%32)=O)CC(C)C)=O)CC(N)=O)=O)CO)=O)=O)CC(N)=O)=O)Cc%33[nH]cnc%33)=O)C)=O)=O)=O)CCC(N)=O)=O)=O)CC(C)C)=O)=O)CC(N)=O)=O)CO)=O)=O)CC(N)=O)=O)CO)=O)CCCCN)=O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 14,875.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Svedbom A, Paech D, Leonard C, Donnell D, Song F, Boszcyk B, Rothenfluh DA, Lloyd A, Borgman B. Is dibotermin alfa a cost-effective substitute for autologous iliac crest bone graft in single level lumbar interbody spine fusion? Curr Med Res Opin. 2015 Nov;31(11):2145-56. doi: 10.1185/03007995.2015.1092123. Epub 2015 Oct 6. PMID: 26359326. 2: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Apr;25(3):225-48. PMID: 12743628. 3: Bouvy JC, Ebbers HC, Schellekens H, Koopmanschap MA. The cost-effectiveness of periodic safety update reports for biologicals in Europe. Clin Pharmacol Ther. 2013 May;93(5):433-42. doi: 10.1038/clpt.2013.13. Epub 2013 Jan 24. PMID: 23549148. 4: Ehnert S, Aspera-Werz RH, Freude T, Reumann MK, Ochs BG, Bahrs C, Schröter S, Wintermeyer E, Nussler AK, Pscherer S. Distinct Gene Expression Patterns Defining Human Osteoblasts' Response to BMP2 Treatment: Is the Therapeutic Success All a Matter of Timing? Eur Surg Res. 2016;57(3-4):197-210. doi: 10.1159/000447089. Epub 2016 Jul 22. PMID: 27441597. 5: Emmerich IU. Neue Arzneimittel für Kleintiere 2013 [New drugs for small animals in 2013]. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2014;42(4):240-8. German. PMID: 25119632. 6: Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Börner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, van der Velde D, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G, Mathevon H, McCoy G, Marsh D, Miller R, Munting E, Oevre S, Nordsletten L, Patel A, Pohl A, Rennie W, Reynders P, Rommens PM, Rondia J, Rossouw WC, Daneel PJ, Ruff S, Rüter A, Santavirta S, Schildhauer TA, Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne RB, Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T; BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002 Dec;84(12):2123-34. doi: 10.2106/00004623-200212000-00001. PMID: 12473698.